Get started
Work

Données de survie globale de l’étude COLUMBUS, étude de phase III avec encorafénib (ENCO) plus binimétinib (BINI) versus vémurafénib (VEM) ou encorafénib (ENCO) dans le mélanome métastatique BRAF muté

Year: 2018
Type: article
DOI: 10.1016/j.annder.2018.09.103
Authors: C. Robert, R. Dummer, P.A. Ascierto, H.J. Gogas, A. Arance, M. Mandala, G. Liszkay, C. Garbe, D. Schadendorf, I. Krajsova, R. Gutzmer, V. Chiarion Sileni, C. Dutriaux, J.W.B. de Groot, N. Yamazaki, C. Loquai, L.A. Moutouh-de Parseval, M.D. Pickard, V. Sandor, K.T. Flaherty
Institutions: Université Paris-Sud, Institut Gustave Roussy, University Hospital Zurich, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", National and Kapodistrian University of Athens, Laiko General Hospital of Athens, Hospital Clínic de Barcelona, Ospedale Papa Giovanni XXIII, National Institute of Oncology, Universitätsklinikum Tübingen, Essen University Hospital, Charles University, Deutsches Konsortium für Translationale Krebsforschung, Medizinische Hochschule Hannover, Istituto Oncologico Veneto, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Isala, National Cancer Center Hospital, University Medical Center of the Johannes Gutenberg University Mainz, Novartis (Switzerland), Array BioPharma (United States), Massachusetts General Hospital
Language: French
Open Access status: closed
OpenAlex ID: W2902769814
FWCI:
Cites:
Cited by:
Related to: 10